

**PANGENOMIC HEALTH INC.**  
**(formerly Zetta Capital Corp.)**

Condensed Interim Consolidated Financial Statements

Nine Months Ended September 30, 2022

(Expressed in Canadian Dollars)

(Unaudited)

**Notice of No Auditor Review**

The accompanying unaudited condensed interim consolidated financial statements of Pangenomic Health Inc. (formerly Zetta Capital Corp.) (the “Company”) have been prepared by management and approved by the Audit Committee and Board of Directors of the Company. The Company’s independent auditors have not performed a review or audit of these condensed interim consolidated financial statements.

**PANGENOMIC HEALTH INC.**

(formerly Zetta Capital Corp.)

Condensed Interim Consolidated Statements of Financial Position

(Expressed in Canadian Dollars)

	September 30, 2022 \$ (Unaudited)	December 31, 2021 \$ (Audited)
<b>ASSETS</b>		
Current assets		
Cash and cash equivalents	28,117	1,348,622
Amounts receivable (Note 3)	124,967	41,366
Prepaid expenses	380,262	280,420
<b>Total current assets</b>	<b>533,346</b>	<b>1,670,408</b>
Non-current assets		
Equipment (Note 5)	22,742	24,880
Intangible assets (Note 6)	926,000	850,000
Loan receivable (Note 4)	34,446	31,640
<b>Total non-current assets</b>	<b>983,188</b>	<b>906,520</b>
<b>TOTAL ASSETS</b>	<b>1,516,534</b>	<b>2,576,928</b>
<b>LIABILITIES</b>		
Current liabilities		
Accounts payable and accrued liabilities	239,506	170,794
Due to related parties (Note 7)	76,781	163,660
<b>Total liabilities</b>	<b>316,287</b>	<b>334,454</b>
<b>SHAREHOLDERS' EQUITY</b>		
Common shares (Note 8)	6,302,141	4,634,568
Preferred shares (Note 9)	–	497,330
Equity reserves (Note 10 and 11)	514,884	97,770
Deficit	(5,616,778)	(2,987,194)
<b>Total shareholders' equity</b>	<b>1,200,247</b>	<b>2,242,474</b>
<b>TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</b>	<b>1,516,534</b>	<b>2,576,928</b>

Nature of operations and continuance of business (Note 1)

Commitment (Note 14)

Subsequent events (Note 15)

Approved and authorized for issuance on behalf of the Board of Directors on November 28, 2022:

Signed: "Vincent Lum"  
\_\_\_\_\_  
Vincent Lum, Director

Signed: "Robert Nygren"  
\_\_\_\_\_  
Robert Nygren

(The accompanying notes are an integral part of these condensed interim consolidated financial statements)

**PANGENOMIC HEALTH INC.**

(formerly Zetta Capital Corp.)

Condensed Interim Consolidated Statements of Operations and Comprehensive Loss

(Expressed in Canadian Dollars)

(Unaudited)

	Three months ended September 30,		Nine months ended September 30,	
	2022	2021	2022	2021
	\$	\$	\$	\$
<b>Expenses</b>				
Advertising and promotion	164,130	–	364,734	–
Consulting fees (Note 7)	237,428	66,000	730,937	143,000
Depreciation (Note 5)	2,897	–	8,143	–
General and administrative	23,760	773	47,432	3,306
Professional fees	71,308	48,532	228,205	90,968
Rent	3,000	3,000	9,000	9,000
Research and development	118,584	–	469,728	–
Share-based compensation (Notes 10 and 11)	214,899	2,558	417,114	12,249
Transfer agent and filing fees	26,013	2,066	34,395	9,503
Wages and benefits (Note 7)	140,720	–	322,728	–
<b>Total expenses</b>	<b>1,002,739</b>	<b>122,929</b>	<b>2,632,416</b>	<b>268,026</b>
<b>Loss before other income (expense)</b>	<b>(1,002,739)</b>	<b>(122,929)</b>	<b>(2,632,416)</b>	<b>(268,026)</b>
<b>Other income (expense)</b>				
Interest expense	(331)	–	(388)	(2,466)
Interest income	481	6,983	1,891	12,414
Foreign exchange translation loss	2,127	–	1,329	–
<b>Total other income (expense)</b>	<b>2,277</b>	<b>6,983</b>	<b>2,832</b>	<b>9,948</b>
<b>Net loss and comprehensive loss for the period</b>	<b>(1,000,462)</b>	<b>(115,946)</b>	<b>(2,629,584)</b>	<b>(258,078)</b>
<b>Loss per common share, basic and diluted</b>	<b>(0.02)</b>	<b>(0.01)</b>	<b>(0.06)</b>	<b>(0.02)</b>
<b>Weighted average common shares outstanding</b>	<b>63,175,081</b>	<b>20,379,349</b>	<b>47,175,284</b>	<b>14,454,857</b>

(The accompanying notes are an integral part of these condensed interim consolidated financial statements)

**PANGENOMIC HEALTH INC.**

(formerly Zetta Capital Corp.)

Condensed Interim Consolidated Statements of Changes in Equity

(Expressed in Canadian Dollars)

(Unaudited)

	Common shares		Preferred shares		Subscriptions received \$	Equity reserves \$	Deficit \$	Total shareholders' equity \$
	Number of shares	Amount \$	Number of shares	Amount \$				
Balance, December 31, 2020	5,869,355	200,324	–	–	148,500	–	(337,872)	10,952
Issuance of units for cash	19,912,642	2,669,896	–	–	(148,500)	–	–	2,521,396
Share issuance costs	–	(63,812)	–	–	–	1,448	–	(62,364)
Issuance of units to settle debt	1,301,309	79,977	–	–	–	–	–	79,977
Issuance of Series B preferred shares for cash	–	–	9,000,000	450,000	–	–	–	450,000
Share-based compensation	–	–	–	–	–	12,249	–	12,249
Net loss for the period	–	–	–	–	–	–	(258,078)	(258,078)
<b>Balance, September 30, 2021</b>	<b>27,083,306</b>	<b>2,886,385</b>	<b>9,000,000</b>	<b>450,000</b>	<b>–</b>	<b>13,697</b>	<b>(595,950)</b>	<b>2,754,132</b>
Balance, December 31, 2021	38,749,973	4,634,568	10,000,000	497,330	–	97,770	(2,987,194)	2,242,474
Issuance of units for cash	7,365,999	1,104,900	–	–	–	–	–	1,104,900
Share issuance costs	–	(9,657)	–	–	–	–	–	(9,657)
Conversion of Series B preferred shares to common shares	25,000,000	497,330	(10,000,000)	(497,330)	–	–	–	–
Issuance of shares for acquisition of intangible asset	500,000	75,000	–	–	–	–	–	75,000
Share-based compensation	–	–	–	–	–	417,114	–	417,114
Net loss for the period	–	–	–	–	–	–	(2,629,584)	(2,629,584)
<b>Balance, September 30, 2022</b>	<b>71,615,972</b>	<b>6,302,141</b>	<b>–</b>	<b>–</b>	<b>–</b>	<b>514,884</b>	<b>(5,616,778)</b>	<b>1,200,247</b>

(The accompanying notes are an integral part of these condensed interim consolidated financial statements)

**PANGENOMIC HEALTH INC.**

(formerly Zetta Capital Corp.)

Condensed Interim Consolidated Statements of Cash Flows

(Expressed in Canadian Dollars)

(Unaudited)

	Nine months ended	
	September 30,	September 30,
	2022	2021
	\$	\$
Operating activities		
Net loss	(2,629,584)	(258,078)
Items not involving cash:		
Amortization of loan fee	–	2,000
Depreciation expense	8,143	–
Foreign exchange translation loss	(2,806)	–
Share-based compensation	417,114	12,249
Changes in non-cash operating working capital:		
Amounts receivable	(82,989)	(19,742)
Prepaid expenses	(103,455)	(25,000)
Accrued interest receivable	(612)	–
Accounts payable and accrued liabilities	93,992	(11,739)
Due to related parties	(119,203)	15,532
Net cash used in operating activities	(2,419,400)	(284,778)
Investing activities		
Investment in loans receivable	–	(600,000)
Purchase of equipment	(6,005)	–
Net cash used in investing activities	(6,005)	(600,000)
Financing activities		
Proceeds from issuance of units, net of issuance costs	1,104,900	2,459,032
Proceeds from issuance of preferred shares	–	450,000
Proceeds from loan payable	–	20,000
Net cash provided by financing activities	1,104,900	2,929,032
Change in cash and cash equivalents	(1,320,505)	2,044,254
Cash and cash equivalents, beginning of period	1,348,622	38,227
Cash and cash equivalents, end of period	28,117	2,082,481
Cash and cash equivalents consist of:		
Cash in bank	16,867	582,481
Cashable short-term investment certificate	11,250	1,500,000
Total cash and cash equivalents	28,117	2,082,481
Supplemental disclosures:		
Interest paid	–	–
Income taxes paid	–	–
Non-cash investing and financing activities:		
Issuance of common shares for acquisition of intangible asset	75,000	–
Issuance of units to settle loan payable	–	79,977
Issuance of broker's warrants	–	1,448

(The accompanying notes are an integral part of these condensed interim consolidated financial statements)

# **PANGENOMIC HEALTH INC.**

(formerly Zetta Capital Corp.)

Notes to the Condensed Interim Consolidated Financial Statements

September 30, 2022

(Expressed in Canadian Dollars)

(Unaudited)

## **1. Nature of Operations and Continuance of Business**

Pangenomic Health Inc. (formerly Zetta Capital Corp.) (the “Company”) was incorporated under the laws of the province of British Columbia, Canada, on December 11, 2015. On December 6, 2021, the Company changed its name from Zetta Capital Corp. to Pangenomic Health Inc. The address of the Company’s corporate office and principal place of business is 102 – 3800 Wesbrook Mall, Vancouver, BC, V6S 2L9. The Company’s common shares trade on the Canadian Stock Exchange (“CSE”) under the symbol “NARA”.

On March 11, 2020, the World Health Organization declared COVID-19 a global pandemic. This contagious disease outbreak and any related adverse public health developments, has adversely affected workforces, economies, and financial markets globally, leading to an economic downturn. The impact on the Company has not been significant, but management continues to monitor the situation.

These condensed interim consolidated financial statements have been prepared on the basis that the Company will continue as a going concern, which assumes that the Company will be able to realize its assets and satisfy its liabilities in the normal course of business for the foreseeable future. Management is aware, in making its going concern assessment, of material uncertainties related to events and conditions that may cast significant doubt upon the Company’s ability to continue as a going concern. For the period ended September 30, 2022, the Company has not generated any revenues and has negative cash flow of from operations. As at September 30, 2022, the Company has an accumulated deficit of \$5,616,778. The continued operations of the Company are dependent on future profitable operations, management’s ability to manage costs and the future availability of equity or debt financing. Whether and when the Company can generate sufficient operating cash flows to pay for its expenditures and settle its obligations as they fall due is uncertain. These condensed interim consolidated financial statements do not reflect the adjustments to the carrying values of assets and liabilities and the reported expenses and statement of financial position classifications that would be necessary were the going concern assumption inappropriate. These adjustments could be material.

## **2. Basis of Presentation**

### **(a) Statement of Compliance**

These condensed interim consolidated financial statements have been prepared in accordance with IAS 34, *Interim Financial Reporting*. The condensed interim consolidated financial statements of the Company should be read in conjunction with the Company’s annual audited financial statements for the year ended December 31, 2021, which were prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”).

### **(b) Basis of Presentation**

These condensed interim consolidated financial statements have been prepared on a historical cost basis. In addition, these condensed interim consolidated financial statements have been prepared using the accrual basis of accounting, except for the cash flow information. In the opinion of the Company’s management, all adjustments considered necessary for a fair presentation have been included.

These condensed interim consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Pangenomic Technologies Corp. (“PTC”) and PlantGX Diagnostics Inc. (“PlantGX”), which were incorporated on in the province of British Columbia, Canada. All intercompany transactions have been eliminated on consolidation.

## **PANGENOMIC HEALTH INC.**

(formerly Zetta Capital Corp.)

Notes to the Condensed Interim Consolidated Financial Statements

September 30, 2022

(Expressed in Canadian Dollars)

(Unaudited)

### **2. Basis of Presentation** (continued)

#### (c) Significant Accounting Estimates and Judgments

The preparation of these condensed interim consolidated financial statements in accordance with IFRS requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, income, and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

Significant areas requiring the use of estimates include the recoverability of loan receivable, useful lives and carrying values of equipment, carrying value of intangible assets, and the fair value of share-based payments.

#### Recoverability of Loan Receivable

The recoverability of loan receivable is assessed by management at the reporting date by applying the expected credit loss impairment model. The model reflects historical loss experiences, facts and circumstances that have existed during the period, informed credit assessment, and consideration of forward-looking information. If actual credit losses differ from estimates, future earnings would be affected.

#### Carrying Value of Equipment and Intangible Asset

The Company assesses impairment of non-financial assets such as equipment and intangible asset. In assessing impairment, management estimates the recoverable amount of each asset or cash generating unit ("CGU") based on expected future cash flows. When measuring expected future cash flows, management makes assumptions about future growth of profits which relate to future events and circumstances. Actual results could vary from these estimated future cash flows. Estimation uncertainty relates to assumptions about future operating results and the application of an appropriate discount rate.

Long-lived assets are reviewed for impairment by determining the recoverable amount of each CGU or groups of CGUs to which the long-lived assets relate. Management estimates the recoverable amount of the CGUs based on the higher of value-in-use ("VIU") and fair value less costs of disposal ("FVLCD"). The VIU calculations are based on expected future cash flows. When measuring expected future cash flows, management makes key assumptions about future growth of profits which relate to future events and circumstances. Estimation uncertainty relates to assumptions about future operating results and the application of an appropriate discount rate. Actual results could vary from these estimates which may cause significant adjustments to the Company's long-lived assets in subsequent reporting periods.

#### Share-based Payments

Fair values of share-based payments are determined using the Black-Scholes option pricing model. Estimating fair value requires determining the most appropriate valuation model for a grant of equity instruments, which is dependent on the terms and conditions of the grant. Option-pricing models require the use of highly subjective estimates and assumptions including the expected stock price volatility. Changes in the underlying assumptions can materially affect the fair value estimates and, therefore, existing models do not necessarily provide reliable measurement of the fair value of the Company's stock options and performance warrants.



## PANGENOMIC HEALTH INC.

(formerly Zetta Capital Corp.)

Notes to the Condensed Interim Consolidated Financial Statements

September 30, 2022

(Expressed in Canadian Dollars)

(Unaudited)

### 2. Basis of Presentation (continued)

#### (c) Significant Accounting Estimates and Judgments (continued)

##### *Significant Judgments*

The critical judgments that the Company's management has made in the process of applying the Company's accounting policies that have the most significant effect on the amounts recognized in the Company's condensed interim consolidated financial statements are as follows:

##### Going Concern

Management has applied judgments in the assessment of the Company's ability to continue as a going concern when preparing its condensed interim consolidated financial statements for the period ended September 30, 2022. Management prepares the condensed interim consolidated financial statements on a going concern basis unless management either intends to liquidate the entity or to cease trading, or has no realistic alternative but to do so. In assessing whether the going concern assumption is appropriate, management takes into account all available information about the future, which is at least, but is not limited to, twelve months from the end of the reporting period. Management considered a wide range of factors relating to current and expected profitability, debt repayment schedules and potential sources of replacement financing. As a result of the assessment, management concluded there is a significant doubt as to the ability of the Company to meet its obligations as they fall due and, accordingly, the ultimate appropriateness of the use of accounting principles applicable to a going concern.

#### (d) Accounting Standards Issued But Not Yet Effective

A number of new standards, and amendments to standards and interpretations, are not yet effective for the period ended September 30, 2022, and have not been early adopted in preparing these condensed interim consolidated financial statements. These new standards, and amendments to standards and interpretations are either not applicable or are not expected to have a significant impact on the Company's condensed interim consolidated financial statements.

### 3. Amounts Receivable

	September 30, 2022 \$	December 31, 2021 \$
Accrued interest receivable	1,791	1,210
GST receivable	111,721	40,156
Wage subsidy receivable	11,200	–
Other receivables	255	–
	124,967	41,366

### 4. Loan Receivable

On November 23, 2021, the Company entered into an agreement with The Horizons Center Public Benefit Corporation ("Horizons") whereby the Company can invest up to US\$1,000,000 in convertible promissory notes which bear interest at 6% per annum and will be due on the two year anniversary of the date as of which the first of the convertible notes is issued. The promissory note is convertible upon the initial closing of the sale of equity securities by Horizons of at least US\$500,000 ("Qualified Financing") into shares of Horizons at 90% of the price per equity for the Qualified Financing. Upon the initial closing of the sale of equity securities by Horizons that is not a Qualified Financing ("Non-Qualified Financing"), the total debt is to be repaid and at the option of the Company, the note can be converted into shares of Horizon at 90% of the price per equity for the Non-Qualified Financing.

## PANGENOMIC HEALTH INC.

(formerly Zetta Capital Corp.)

Notes to the Condensed Interim Consolidated Financial Statements

September 30, 2022

(Expressed in Canadian Dollars)

(Unaudited)

### 4. Loan Receivable (continued)

As at September 30, 2022, the Company has invested \$34,446 (US\$25,000) (December 31, 2021 - \$31,640 (US\$25,000)) and recognized accrued interest of \$1,761 (US\$1,278) (December 31, 2021 - \$198 (US\$156)), which is included in amounts receivable (Note 3).

### 5. Equipment

	Computer equipment \$
Cost	
Balance, December 31, 2021	29,629
Additions	6,005
Balance, September 30, 2022	35,634
Depreciation	
Balance, December 31, 2021	4,749
Depreciation	8,143
Balance, September 30, 2022	12,892
Carrying amounts	
Balance, December 31, 2021	24,880
Balance, September 30, 2022	22,742

### 6. Intangible Assets

(a) On October 4, 2021, the Company entered into a share purchase agreement with the shareholders of PGT, whereby the Company acquired 100% of the issued and outstanding common shares of PGT. Upon acquisition, the Company applied the initial measurement requirements in IAS 38, *Intangible Assets*, and determined the intangible asset acquired had a fair value of \$850,000. As the transaction price of \$2,644,042 differed from the fair value, the Company recognized an impairment loss on initial recognition of \$1,794,042 during the year ended December 31, 2021, and recorded the intangible asset at its fair value of \$850,000.

(b) On January 10, 2022, the Company entered into an intellectual property asset purchase agreement with LivNao Technologies Inc. ("LivNao Agreement"). Under the terms of the LivNao Agreement, the Company purchased from LivNao all of LivNao's rights, titles, and interests to the LivNao intellectual property ("LiveNao IP") for 500,000 common shares and cash of \$1,000. In addition, the Company has agreed to issue to LivNao up to 1,500,000 additional common shares upon satisfaction of the of the following milestones on or before March 31, 2023:

- 500,000 common shares upon the Nara App having 100,000 active users;
- 500,000 common shares upon the Nara App having 500,000 active users; and
- 500,000 common shares upon the Nara App having 1,000,000 active users.

On March 16, 2022, the Company issued the 500,000 shares of common stock with a fair value of \$75,000. As at September 30, 2022, the Company has not recognized any additional consideration related to the additional 1,500,000 common shares as it is not reasonably certain that any of the milestones will be met.

## PANGENOMIC HEALTH INC.

(formerly Zetta Capital Corp.)

Notes to the Condensed Interim Consolidated Financial Statements

September 30, 2022

(Expressed in Canadian Dollars)

(Unaudited)

### 7. Related Party Transactions

Key management personnel are the persons responsible for the planning, directing and controlling the activities of the Company and includes both executive and non-executive directors, and entities controlled by such persons. The Company considers all Directors and Officers of the Company to be key management personnel. The following are the remuneration of the Company's related parties:

	Nine Months ended	
	September 30, 2022	September 30, 2021
	\$	\$
Chief Executive Officer ("CEO"), for wages incurred	12,923	–
Chief Financial Officer ("CFO"), for consulting fees	22,250	–
Executive Chair and Director, for consulting fees and wages incurred	100,000	–
Chief Scientific Officer ("CSO"), for consulting fees and wages incurred	86,500	–
Chief Technology Officer ("CTO"), for consulting fees	45,000	–
Company controlled by the CTO, for research and development	457,676	–
Director, for consulting fees	22,500	–
Director, for consulting fees	25,000	–
Director and former CEO, for consulting fees and wages incurred	104,308	–
Former VP Finance, for consulting fees	–	90,000
Former CEO, for consulting fees	–	18,000
Share-based compensation	339,013	–
	1,215,170	108,000

Amounts due to related parties are non-interest bearing, unsecured and due on demand.

	September 30, 2022	December 31, 2021
	\$	\$
CFO	313	–
Executive Chair and Director	(550)	(1,600)
CSO	–	37,869
CTO	5,250	15,730
Company controlled by the CTO	71,768	91,985
Former VP Finance*	–	13,676
Former CEO*	–	6,000
	76,781	163,660

\* Amounts owing to the former VP Finance and former CEO have been reclassified to accounts payable at September 30, 2022.

## PANGENOMIC HEALTH INC.

(formerly Zetta Capital Corp.)

Notes to the Condensed Interim Consolidated Financial Statements

September 30, 2022

(Expressed in Canadian Dollars)

(Unaudited)

### 8. Common Shares

Authorized: Unlimited number of Class A common shares without par value

(a) On March 16, 2022, the Company issued 500,000 common shares with a fair value of \$75,000 pursuant to the LivNao Agreement as described in Note 6(b).

(a) On July 7, 2022, the Company issued 7,365,999 units at \$0.15 per unit for gross proceeds of \$1,104,900. Each unit consists of one common share of the Company and one warrant. Each warrant entitles the holder to purchase one additional common share of the Company at \$0.30 per share for a period of two years, subject to the Company's right to accelerate the expiry date of such warrant if the closing price of the common shares is equal to or greater than \$0.60 per share for 10 consecutive trading days. In connection with the issuance, the Company incurred share issuance costs of \$9,657.

(b) On July 29, 2022, the Company issued 25,000,000 common shares pursuant to the conversion of 10,000,000 Class B preferred shares (Note 9).

### 9. Preferred Shares

Authorized: Unlimited number of Class B preferred shares without par value

The holders of Class B preferred shares shall not be entitled as such to receive notice of, to attend, or to vote at any meeting of the shareholders of the Company. The holders of Class B shares shall, in preference to the holders of the common shares, be entitled to receive dividends and shall be entitled to receive priority in the event of liquidation, dissolution or winding-up of the Company.

On July 29, 2022, the Company converted 10,000,000 preferred shares into 25,000,000 common shares of the Company (Note 8).

### 10. Share Purchase Warrants

The following table summarizes the continuity of the Company's share purchase warrants:

	Number of warrants	Weighted average exercise price \$
Balance, December 31, 2021	22,229,911	0.26
Issued	10,365,999	0.26
Balance, September 30, 2022	32,595,910	0.26
Exercisable, September 30, 2022	29,595,910	0.27

## PANGENOMIC HEALTH INC.

(formerly Zetta Capital Corp.)

Notes to the Condensed Interim Consolidated Financial Statements

September 30, 2022

(Expressed in Canadian Dollars)

(Unaudited)

### 10. Share Purchase Warrants (continued)

As at September 30, 2022, the following share purchase warrants were outstanding:

Number of warrants outstanding	Number of warrants exercisable	Exercise price \$	Expiry date	Weighted average remaining contracted life (years)
4,322,198	4,322,198	0.10	January 13, 2023	0.29
500,000	500,000	0.10	January 21, 2023	0.31
4,098,453	4,098,453	0.30	April 22, 2023	0.56
6,945,294	6,945,294	0.30	July 23, 2023	0.81
5,863,966	5,863,966	0.30	September 16, 2023	0.96
500,000	500,000	0.30	October 25, 2023	1.07
7,365,999	7,365,999	0.30	July 11, 2024	1.78
3,000,000	—	0.15	July 1, 2025	2.75
<u>32,595,910</u>	<u>29,595,910</u>			

Share-based compensation expense is determined using the Black-Scholes option pricing model. During the period ended September 30, 2022, the Company recognized share-based compensation expense of \$123,436 (2021 - \$12,249) in equity reserves related to the performance warrants, of which \$123,436 (2021 - \$12,249) pertains to officers and directors of the Company. The weighted average fair value of options granted during the period ended September 30, 2022, was \$0.12 (2021 - \$0.03) per share. Weighted average assumptions used in calculating the fair value of share-based compensation expense related to the performance warrants are as follows:

	2022	2021
Risk-free interest rate	3.14%	0.17%
Dividend yield	0%	0%
Expected volatility	150%	150%
Expected life (years)	3.00	2.00
Forfeiture rate	0%	0%

### 11. Stock Options

On December 27, 2021, the Company adopted a stock option plan providing for the grant of stock options to purchase Class A common shares to officers, directors, employees, and consultants in an amount equal to up to 20% of the issued and outstanding common shares. The exercise price is determined by the Board of Directors. Stock options are granted for a maximum term of 10 years.

## PANGENOMIC HEALTH INC.

(formerly Zetta Capital Corp.)

Notes to the Condensed Interim Consolidated Financial Statements

September 30, 2022

(Expressed in Canadian Dollars)

(Unaudited)

### 11. Stock Options (continued)

The following table summarizes the continuity of the Company's stock options:

	Number of stock options	Weighted average exercise price \$
Balance, December 31, 2021	2,065,000	0.15
Granted	2,190,000	0.19
Cancelled	(175,000)	0.15
<b>Balance, September 30, 2022</b>	<b>4,080,000</b>	<b>0.17</b>
<b>Exercisable, September 30, 2022</b>	<b>1,466,760</b>	<b>0.15</b>

Additional information regarding stock options outstanding as at September 30, 2022, is as follows:

Number of stock options outstanding	Number of stock options exercisable	Exercise price \$	Expiry date	Weighted average remaining contracted life (years)
150,000	–	0.15	October 31, 2024	2.09
1,890,000	1,076,760	0.15	December 27, 2024	2.24
1,000,000	375,000	0.15	January 10, 2025	2.28
10,000	–	0.30	February 28, 2025	2.42
30,000	15,000	0.25	July 19, 2024	1.80
1,000,000	–	0.23	September 6, 2025	2.94
<b>4,080,000</b>	<b>1,466,760</b>			

Share-based compensation expense is determined using the Black-Scholes option pricing model. During the period ended September 30, 2022, the Company recognized share-based compensation expense of \$293,678 (2021 - \$nil) in equity reserves, of which \$215,577 (2021 - \$nil) pertains to officers and directors of the Company. The weighted average fair value of options granted during the period ended September 30, 2022, was \$0.16 (2021 – \$nil) per share. Weighted average assumptions used in calculating the fair value of share-based compensation expense are as follows:

	2022
Risk-free interest rate	2.66%
Dividend yield	0%
Expected volatility	163%
Expected life (years)	2.84
Forfeiture rate	0%

## **PANGENOMIC HEALTH INC.**

(formerly Zetta Capital Corp.)

Notes to the Condensed Interim Consolidated Financial Statements

September 30, 2022

(Expressed in Canadian Dollars)

(Unaudited)

### **12. Financial Instruments and Risk Management**

#### (a) Fair Values

Fair value measurements are classified using a fair value hierarchy that reflects the significance of inputs used in making the measurements. The fair value hierarchy has the following levels:

- Level 1 - valuation based on quoted prices (unadjusted) in active markets for identical assets or liabilities;
- Level 2 - valuation techniques based on inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and
- Level 3 - valuation techniques using inputs for the asset or liability that are not based on observable market data (unobservable inputs).

The fair values of financial instruments, which includes cash and cash equivalents, amounts receivable (except GST receivable), loan receivable, accounts payable and accrued liabilities, and amounts due to related parties, approximate their carrying values due to the relatively short-term maturity of these instruments.

#### (b) Credit Risk

Credit risk is the risk of loss that may arise on outstanding financial instruments should a counterparty default on its obligation. Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and loans receivable. The Company minimizes its credit risk associated with its cash balance by dealing with major financial institutions in Canada. The carrying amount of financial assets represents the maximum credit exposure.

#### (c) Foreign Exchange Rate Risk

Foreign exchange risk is the risk that the Company's financial instruments will fluctuate in value as a result of movements in foreign exchange rates. The Company is not exposed to any significant foreign exchange rate risk.

#### (d) Interest Rate Risk

Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company is not exposed to interest rate risk as it does not have any assets or liabilities that are affected by changes in interest rates.

#### (e) Liquidity Risk

Liquidity risk is the risk that the Company will encounter difficulty in meeting financial obligations due to shortage of funds. The Company manages liquidity risk by maintaining sufficient cash balances and adjusting its operating budget and expenditure. Liquidity requirements are managed based on expected cash flows to ensure that there is sufficient capital in order to meet short-term and other specific obligations.

## **PANGENOMIC HEALTH INC.**

(formerly Zetta Capital Corp.)

Notes to the Condensed Interim Consolidated Financial Statements

September 30, 2022

(Expressed in Canadian Dollars)

(Unaudited)

### **13. Capital Management**

The Company manages its capital structure and makes adjustments to it, based on the funds available to the Company, in order to support the general operations of the Company and facilitate the liquidity needs of its operations. The Board of Directors does not establish quantitative return on capital criteria for management, but rather relies on the expertise of the Company's management to sustain future development of the business. The Company defines capital to include its working capital position, share capital, and accumulated deficit.

Management reviews its capital management approach on an ongoing basis and believes that this approach, given the relative size of the Company, is reasonable. There were no changes in the Company's approach to capital management during the period ended September 30, 2022. The Company is not subject to externally imposed capital requirements.

### **13. Commitment**

On July 18, 2022, the Company entered into an agreement for market making services for an initial term of 6 months in consideration for \$7,500 per month, payable quarterly, with such fee subject to an annual increase of 3%. The agreement automatically renews for successive 6 month terms unless terminated by the Company.

### **15. Subsequent Events**

(a) On November 18, 2022, the Company entered into a definitive share exchange agreement ("Share Exchange Agreement") with Mydecine Innovations Group Inc., ("Mydecine ") whereby the Company has agreed to acquire 100% of the issued and outstanding shares of Mydecine's wholly-owned subsidiary, Mindleap Health Inc ("Mindleap") for a purchase price of \$3,600,000, payable by the issuance of units at a deemed price of \$0.20 per unit, or such greater price as may be required by the CSE, per unit. Each unit will consist of one common share of the Company and one warrant. Each warrant will entitle the holder to purchase one additional common share of the Company at a price of \$0.30, or such greater price as may be required by the CSE, per share for a period of two years from the closing of the purchase and sale of Mindleap shares. The closing of the transaction is subject to regulatory approvals.

In addition, the Company and Mindleap are expected to enter into a transition services agreement upon closing of the Share Exchange Agreement, whereby the Company will engage Mindleap to assist in the transition, transfer, and integration of Mindleap technologies into PanGenomic's technology platform for two months following the closing. As consideration, the Company shall pay a monthly consulting fee of \$50,000.

In connection with the Share Exchange Agreement, the Company entered into a fee agreement with two third party consultants for introductory and advisory services in consideration for \$400,000 upon closing, to be paid by the issuance of units at a deemed price of \$0.20 per unit. The finder's units have the same terms as the units being issued to acquire Mindleap.

(b) On October 17, 2022, the Company issued a total of 1,080,000 common shares upon the exercise of share purchase warrants at \$0.10 per share for gross proceeds of \$108,000.